Bifidumbacterin, and topical application 5 doses 30 pcs

Pharmacotherapeutic group

Medical immunobiological drug – probiotic. ATX code: A07FA.

BIOLOGICAL PROPERTIES

Therapeutic properties of the drug are determined by live lyophilized bifidobacteria (Bifidobacterium bifidum) inherent in humans since birth, having antagonistic activity against a wide range of pathogenic and conditionally pathogenic microorganisms. The high quantitative level of bifidobacteria in the product allows to normalize the intestinal microflora and thereby improve the activity of the gastrointestinal tract, metabolic processes, fasting digestion, increase nonspecific resistance of the body.

Indications

Dysbacteriosis of the intestines of various etiologies.

In the complex therapy: intestinal dysfunctions of unspecified etiology; acute intestinal infections (dysentery, salmonellosis, escherichiosis, yersiniosis, rotavirus infection of unspecified etiology); People who recovered from acute intestinal infections;

Chronic diseases of the digestive system with abnormal intestinal microflora;

Chronic diseases of the digestive system with abnormal intestinal microfloraIn children (including infants and prematurely born) with pneumonia, sepsis and other purulent-infectious diseases as well as in case of anemia, hypotrophy, rickets in order to decrease the complications and increase the effectiveness of the main treatment; Allergic diseases;

dysbiosis and inflammatory processes of female genitalia (bacterial vaginosis, including in pregnant women, bacterial colpitis, and senile colpitis of hormonal nature).

To prevent dysbacteriosis when taking antibacterial drugs (including antibiotics), glucocorticosteroids, drugs with ulcerogenic effect on the gastrointestinal tract (including NSAIDs). NSAIDs);

Radiation and chemotherapy;

Stress and extremes; children of all ages with a history of illnesses;

Children with a history of pre-morbid conditions, those born prematurely or with signs of prematurity and those who received antibiotics in the early neonatal period.Children whose mothers have had severe toxemia, extragenital diseases, prolonged waterless period, lactastasis, cracked nipples and resumed breastfeeding after recovery from mastitis;

Infants who are breastfed when they are switched to artificial feeding and donor milk early.

For the purpose of mastitis prevention for local mammary gland treatment in breastfeeding mothers of the “risk” group (in women with inverted flat nipple, decreased nipple erection, the presence of cracks).

Active ingredient

Composition

Effective ingredient – bifidobacteria – at least 500 million (5×108 CFU)

supplementary substance – lactose monohydrate – up to 0.85 g

How to take, the dosage

The number of times the drug can be increased up to 6 times a day, if necessary.

The course of treatment is 3-4 weeks. If necessary the course of treatment may be repeated 2 or 3 times with each course in a month.

In acute cases of severe disease with severe dysbacteriosis the daily dose of the drug may be increased only upon the prescription of the attending physician. When using the drug in the complex treatment of acute intestinal infections the course of treatment is 7-10 days. For preventive purposes:

Interaction

Special Instructions

Synopsis

Contraindications

Side effects

Overdose

Pregnancy use

Similarities